These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12859583)

  • 1. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program.
    Etemad LR; Hay JW
    Value Health; 2003; 6(4):425-35. PubMed ID: 12859583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
    Moran A; Goldman L
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):606-7. PubMed ID: 18695697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
    Lewis JH; Schonlau M; Muñoz JA; Asch SM; Rosen MR; Yang H; Escarce JJ
    N Engl J Med; 2002 Mar; 346(11):830-5. PubMed ID: 11893795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
    Ito K; Elkin E; Blinder V; Keating N; Choudhry N
    Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular medicine, the Medicare drug benefit, and the need for cost control.
    Gillick MR
    J Am Geriatr Soc; 2006 Sep; 54(9):1442-6. PubMed ID: 16970656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Chisholm MA; Marshall J; Smith KE; Garrett CJ; Turner JC
    Clin Transplant; 2005 Jun; 19(3):357-63. PubMed ID: 15877798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare risk programs and pharmacy benefits managers.
    Herzfeld J
    Med Interface; 1996 Dec; 9(12):75-8. PubMed ID: 10172875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacy utilization and the Medicare Modernization Act.
    Maio V; Pizzi L; Roumm AR; Clarke J; Goldfarb NI; Nash DB; Chess D
    Milbank Q; 2005; 83(1):101-30. PubMed ID: 15787955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifting the focus from cost to value: a government perspective.
    Edgar BS
    J Manag Care Pharm; 2006 Aug; 12(6 Suppl B):S11-5; quiz S24-6. PubMed ID: 17274691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing an integrated drug benefit for the elderly.
    King AB; Colligen BH; Levy RA; Cohen KR
    J Am Health Policy; 1994; 4(4):41-5. PubMed ID: 10136682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois--A qualitative study.
    Bono JD; Crawford SY
    Res Social Adm Pharm; 2010 Jun; 6(2):110-20. PubMed ID: 20511110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacy and Therapeutics Committee implications of the Medicare drug benefit.
    Penna P
    Manag Care Interface; 2004 Mar; 17(3):42-3. PubMed ID: 15098550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.